Grants and Contracts Details
Description
22-GI-127-RP: Phase 2 Single-Arm Study of Nanoliposomal Irinotecan with Fluorouracil and Leucovorin in Refractory
Advanced High-Grade Neuroendocrine Cancer of GI, Unknown, or Pancreatic Origin
Primary Objective
1.To determine the objective response rate of nanoliposomal irinotecan (Nal-IRI) + fluorouracil (5-FU) and leucovorin
in patients with refractory advanced high-grade neuroendocrine cancer of GI, unknown, or pancreatic origin.
Secondary Objective
1.To determine overall survival, progression-free survival, time to treatment failure, safety, clinical response and,
quality of life (QOL) changes resulting from the combination treatment of nanoliposomal irinotecan (Nal-IRI) +
fluorouracil (5-FU) and leucovorin.
| Status | Finished |
|---|---|
| Effective start/end date | 9/7/22 → 9/7/22 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.